Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2003 Dec;62(12):1204-7.
doi: 10.1136/ard.2002.003889.

Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren's syndrome: a randomised 12 week controlled study

N Tsifetaki  1 , G Kitsos, C A Paschides, Y Alamanos, V Eftaxias, P V Voulgari, K Psilas, A A Drosos
Affiliations
Clinical Trial

Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren's syndrome: a randomised 12 week controlled study

N Tsifetaki et al. Ann Rheum Dis. 2003 Dec.

Abstract

Objective: To evaluate the efficacy and side effects of oral pilocarpine for the treatment of ocular symptoms in patients with primary Sjögren's syndrome (SS).

Methods: A 12 week, single centre, randomised controlled study was performed. Twenty nine patients were randomly assigned to receive oral pilocarpine (5 mg twice a day), 28 only artificial tears, and 28 inferior puncta occlusion. Patients receiving oral pilocarpine and those with inferior puncta occlusion also received artificial tears. Patients were evaluated at baseline and throughout the study for their subjective global assessment of dry eyes and for their objective assessment of dry eyes (Schirmer's-I test, rose bengal test, and imprint test).

Results: Patients taking oral pilocarpine had significant improvement in subjective global assessment of dry eyes, as was evaluated by improvement of >55 mm on a visual analogue scale (VAS) for responses to the eye questionnaire, compared with patients treated with artificial tears (p<0.001) and those with inferior puncta occlusion (p<0.05). Furthermore, patients receiving oral pilocarpine also showed greater objective improvement, as measured by the rose bengal test (p<0.05), while Schirmer's-I test showed no differences between the treated groups. Commonly reported adverse events were headache, increased sweating, nausea, and vomiting in the pilocarpine group, while one patient in the inferior puncta occlusion group had blepharitis and was withdrawn from the study.

Conclusion: 10 mg of pilocarpine daily given to patients with SS for 12 weeks had a beneficial effect on subjective eye symptoms, as evaluated by improvement >55 mm on a VAS. Additionally, an improvement of rose bengal staining was noted, but an increase in tear production, as measured by the Schirmer-I test, was not substantiated.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow of patients and trial profile.
Figure 2
Figure 2
Subjective improvement of occular symptoms in patients with primary SS.
See this image and copyright information in PMC

References

    1. Clin Immunol Immunopathol. 1994 Aug;72(2):162-5 - PubMed
    1. Drugs. 1995 Jan;49(1):143-55 - PubMed
    1. Clin Exp Rheumatol. 1996 Sep-Oct;14(5):555-8 - PubMed
    1. Eur J Pharmacol. 1997 Nov 19;339(1):1-9 - PubMed
    1. Oral Dis. 1997 Jun;3(2):93-8 - PubMed

Publication types